Show simple item record

dc.contributor.authorNorris, JM
dc.contributor.authorCarmona Echeverria, LM
dc.contributor.authorBott, SRJ
dc.contributor.authorBrown, LC
dc.contributor.authorBurns-Cox, N
dc.contributor.authorDudderidge, T
dc.contributor.authorEl-Shater Bosaily, A
dc.contributor.authorFrangou, E
dc.contributor.authorFreeman, A
dc.contributor.authorGhei, M
dc.contributor.authorHenderson, A
dc.contributor.authorHindley, RG
dc.contributor.authorKaplan, RS
dc.contributor.authorKirkham, A
dc.contributor.authorOldroyd, R
dc.contributor.authorParker, C
dc.contributor.authorPersad, R
dc.contributor.authorPunwani, S
dc.contributor.authorRosario, DJ
dc.contributor.authorShergill, IS
dc.contributor.authorStavrinides, V
dc.contributor.authorWinkler, M
dc.contributor.authorWhitaker, HC
dc.contributor.authorAhmed, HU
dc.contributor.authorEmberton, M
dc.identifier.citationEuropean urology, 2020, 78 (2), pp. 163 - 170
dc.description.abstractBackground All risk stratification strategies in cancer overlook a spectrum of disease. The Prostate MR Imaging Study (PROMIS) provides a unique opportunity to explore cancers that are overlooked by multiparametric magnetic resonance imaging (mpMRI).Objective To summarise attributes of cancers that are systematically overlooked by mpMRI.Design, setting, and participants PROMIS tested performance of mpMRI and transrectal ultrasonography (TRUS)-guided biopsy, using 5 mm template mapping (TPM) biopsy as the reference standard.Outcome measurements and statistical analysis Outcomes were overall and maximum Gleason scores, maximum cancer core length (MCCL), and prostate-specific antigen density (PSAD). Cancer attributes were compared between cancers that were overlooked and those that were detected.Results and limitations Of men with cancer, 7% (17/230; 95% confidence interval [CI] 4.4-12%) had significant disease overlooked by mpMRI according to definition 1 (Gleason ≥ 4 + 3 of any length or MCCL ≥ 6 mm of any grade) and 13% (44/331; 95% CI 9.8-17%) according to definition 2 (Gleason ≥ 3 + 4 of any length or MCCL ≥ 4 mm). In comparison, TRUS-guided biopsy overlooked 52% (119/230; 95% CI 45-58%) of significant disease by definition 1 and 40% (132/331; 95% CI 35-45%) by definition 2. Prostate cancers undetected by mpMRI had significantly lower overall and maximum Gleason scores (p = 0.0007; p < 0.0001) and shorter MCCL (median difference: 3 mm [5 vs 8 mm], p < 0.0001; 95% CI 1-3) than cancers that were detected. No tumours with overall Gleason score > 3 + 4 (Gleason Grade Groups 3-5; 95% CI 0-6.4%) or maximum Gleason score > 4 + 3 (Gleason Grade Groups 4-5; 95% CI 0-8.0%) on TPM biopsy were undetected by mpMRI. Application of a PSAD threshold of 0.15 reduced the proportion of men with undetected cancer to 5% (12/230; 95% CI 2.7-8.9%) for definition 1 and 9% (30/331; 95% CI 6.2-13%) for definition 2. Application of a PSAD threshold of 0.10 reduced the proportion of men with undetected disease to 3% (6/230; 95% CI 1.0-5.6%) for definition 1 cancer and to 3% (11/331; 95% CI 1.7-5.9%) for definition 2 cancer. Limitations were post hoc analysis and uncertain significance of undetected lesions.Conclusions Overall, a small proportion of cancers are overlooked by mpMRI, with estimates ranging from 4.4% (lower boundary of 95% CI for definition 1) to 17% (upper boundary of 95% CI for definition 2). Prostate cancers undetected by mpMRI are of lower grade and shorter length than cancers that are detected.Patient summary Prostate cancers that are undetected by magnetic resonance imaging (MRI) are smaller and less aggressive than those that are detected, and none of the most aggressive cancers are overlooked by MRI.
dc.format.extent163 - 170
dc.titleWhat Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort.
dc.typeJournal Article
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean urology
pubs.notesNot known
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.embargo.termsNot known
dc.contributor.icrauthorParker, Chrisen

Files in this item


This item appears in the following collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as